NCT04491474 is a Phase 4 clinical trial of Lidocaine Hydrochloride in Migraine Disorders, sponsored by Dr. Lutfi Kirdar Kartal Training and Research Hospital.

Who is sponsoring NCT04491474?

NCT04491474 is sponsored by Dr. Lutfi Kirdar Kartal Training and Research Hospital.

What drugs are being tested in NCT04491474?

Interventions in NCT04491474: Lidocaine Hydrochloride, Placebo.

What condition does NCT04491474 study?

NCT04491474 studies Migraine Disorders.

Is NCT04491474 still recruiting?

NCT04491474 is currently completed. Last updated 16 March 2021.

Last reviewed 2021-03-16 · How we verify

NCT04491474

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Comparison of Great Occipital Nerve and Supraorbital Nerve Blockade Methods at Treatment of Acute Migraine Attack in the Emergency Department

Completed Phase 4 Last updated 16 March 2021

What this trial tests

Phase 4 trial testing Lidocaine Hydrochloride in Migraine Disorders in 128 participants. Completed in 14 March 2021.

Timeline

15 August 2020

Primary endpoint
14 March 2021

14 March 2021

Quick facts

Lead sponsor	Dr. Lutfi Kirdar Kartal Training and Research Hospital
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	sequential
Masking	triple
Primary purpose	treatment
Enrollment	128
Start date	15 August 2020
Primary completion	14 March 2021
Estimated completion	14 March 2021
Sites	1 location across Turkey (Türkiye)

Drugs / interventions tested

Lidocaine Hydrochloride (Lidocaine Hydrochloride) — full drug profile →
Placebo

Conditions studied

Migraine Disorders — all drugs for Migraine Disorders →

Sponsor

Dr. Lutfi Kirdar Kartal Training and Research Hospital

Who can join

Adults 18 to 50, any sex, with Migraine Disorders. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Aim Acute migraine attack is a clinical condition that is frequently encountered in emergency departments and varies from patient to patient in terms of treatment modalities. There are many different treatments whose effectiveness has been proven by concrete evidence(1). Drug treatments applied to patients are generally given intravenously or intramuscularly. Non-steroidal anti-inflammatory drugs, metoclopramide and intravenous magnesium therapy is generally used for treatment in emergency departments (1). The effectiveness of supraorbital nerve blockade and great occipital nerve blockade in migraine treatment and prophylaxis has been proven in many studies(2-6). The aim of this study is to discuss the effectiveness of supraorbital and great occipital nerve blockade treatments in acute migraine attack, when combined or used individually.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Lidocaine Hydrochloride

Trials testing the same drug.

NCT07205757 — Adding Lidocaine to Custodiol Mixture · Phase 4 · recruiting
NCT07079449 — Comparison of Lidocaine, Mepivacaine, and Dry Needling in Myofascial Pain Syndrome · NA · completed
NCT06662318 — Perioperative Pain Management for Lumbar Spine Surgery · NA · completed
NCT06319534 — Stellate Ganglion Block in Bulbar Palsy · NA · completed
NCT06225076 — Efficacy of Stellate Ganglion Block in Dysphagic Patients With Bulbar Palsy After Ischemic Stroke · NA · withdrawn

Other recruiting trials for Migraine Disorders

Currently open trials in the same condition.

NCT07170176 — Effects of PFO Closure on Glymphatic Function and Clinical Symptoms in Patients With Migraine · NA · recruiting
NCT07093138 — Evaluation of Efficacy and Safety of Topical Cannabidiol (Canvert-M Produced by Alasht Pharmed co. Iran) in the Treatmen · Phase 4 · recruiting
NCT06426316 — The Role of Cytokines and Regulatory T Lymphocytes in Migraine Pathophysiology. · NA · recruiting
NCT06623188 — Treatment of Episodic Migraine With AURICular Neuromodulation · NA · recruiting
NCT06535880 — Trigeminal Brainstem Mapping 2: Higher Cortical Strucureas As Well As Subnuclei of the Spinal Trigeminal Nucleus · NA · recruiting

Other Dr. Lutfi Kirdar Kartal Training and Research Hospital trials

Trials by the same sponsor.

NCT07322497 — Comparison of Video Based Phone App vs. Supervised Preoperative Exercise for ACL Reconstruction · NA · not yet recruiting
NCT07141966 — Assessment of Physical Activity, Balance, Muscle Strength, and Cognitive Function in Patients Diagnosed With Schizophren · completed
NCT07142018 — Investigation of the Effect of Hyperbaric Oxygen Therapy in Patients With Avascular Necrosis · active not recruiting
NCT07144553 — Relationship Between Eating Disorders, Anthropometric Characteristics, and Physical Activity After Bariatric Surgery · completed
NCT07140042 — Physical Fitness, Physical Activity Level, Depression and Quality of Life in Bipolar and Schizophrenia Patients · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04491474 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Dr. Lutfi Kirdar Kartal Training and Research Hospital
Last refreshed: 16 March 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04491474.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing